hVIVO Dividendos y recompras

Dividendo controles de criterios 0/6

hVIVO es una empresa que paga dividendos con una rentabilidad actual de 0.91%.

Información clave

0.9%

Rentabilidad por dividendo

-0.06%

Rendimiento de la recompra

Rendimiento total para el accionista	0.8%
Rendimiento futuro de los dividendos	1.3%
Crecimiento de los dividendos	n/a
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	UK£0.002
Ratio de pago	8%

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

hVIVO plc's (LON:HVO) Intrinsic Value Is Potentially 28% Above Its Share Price

Jan 26

Improved Revenues Required Before hVIVO plc (LON:HVO) Stock's 26% Jump Looks Justified

Jan 03

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: HVO no paga un dividendo notable para el mercado UK, por lo que no es necesario comprobar si los pagos son estables.

Dividendo creciente: HVO no paga un dividendo notable para el mercado UK, por lo que no es necesario comprobar si los pagos aumentan.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de hVIVO vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de HVO con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (HVO)	0.9%
Suelo de mercado 25% (GB)	2.1%
Techo de mercado 25% (GB)	5.9%
Media de la industria (Life Sciences)	0.7%
Analista de previsiones (HVO) (hasta 3 años)	1.3%

Dividendo destacado: El dividendo de HVO(0.91%) no es notable en comparación con el 25% inferior de pagadores de dividendos del mercado UK (2.11%).

Alto dividendo: El (0.91%) del dividendo de HVO es bajo en comparación con el 25% de los principales pagadores de dividendos del mercado UK (5.87%).

Pago de beneficios a los accionistas

Cobertura de los beneficios: HVO no paga un dividendo notable para el mercado UK.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: HVO no paga un dividendo notable para el mercado UK.

hVIVO Dividendos y recompras

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos y recompras

Recent updates

hVIVO plc to Report First Half, 2024 Results on Sep 10, 2024

hVIVO Proposes Cancellation of Admission to Trading on Euronext Growth

Price target increased by 7.2% to UK£0.36

hVIVO plc, Annual General Meeting, May 13, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

hVIVO plc to Report Fiscal Year 2023 Results on Apr 09, 2024

New minor risk - Share price stability

hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.

hVIVO plc's (LON:HVO) Intrinsic Value Is Potentially 28% Above Its Share Price

Improved Revenues Required Before hVIVO plc (LON:HVO) Stock's 26% Jump Looks Justified

hVIVO plc Signs £6.3 Million Human Challenge Study Model

At UK£0.20, Is hVIVO plc (LON:HVO) Worth Looking At Closely?

hVIVO plc Increases Revenue Guidance for 2023

hVIVO plc to Report First Half, 2023 Results on Sep 12, 2023

hVIVO plc to Develop Human Metapneumovirus Challenge Model

A Piece Of The Puzzle Missing From hVIVO plc's (LON:HVO) Share Price

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2023

A Look At The Intrinsic Value Of hVIVO plc (LON:HVO)

hVIVO plc Provides Earnings Guidance for the Full Year 2022

Forecast breakeven date pushed back to 2023

Now 22% undervalued

hVIVO plc Announces Publication of Imutex Phase I Data

Should You Investigate hVIVO plc (LON:HVO) At UK£0.11?

Less than half of directors are independent

Open Orphan plc Announces Chief Financial Officer Changes

Open Orphan plc Announces Positive Data from Peer-Reviewed Study Evaluating the in Vitro Efficacy of Flu-V

Is There An Opportunity With Open Orphan Plc's (LON:ORPH) 41% Undervaluation?

First half 2022 earnings released: EPS: UK£0 (vs UK£0.002 in 1H 2021)

Open Orphan plc Reiterates Revenue Guidance for the Full Year of 2022

Open Orphan Plc to Report First Half, 2022 Results on Sep 08, 2022

Open Orphan plc, Annual General Meeting, Jul 05, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Open Orphan plc Appoints Martin Gouldstone as Independent Non-Executive Director

Are Investors Undervaluing Open Orphan plc (LON:ORPH) By 44%?

Open Orphan plc to Report Fiscal Year 2021 Results on Jun 07, 2022

Forecast breakeven date pushed back to 2022

Less than half of directors are independent

Open Orphan plc Announces Characterisation Study Results in Nature Medicine

Open Orphan plc Appoints Yamin 'Mo' Khan as Chief Executive Officer

First half 2021 earnings released: EPS UK£0.002 (vs UK£0.012 loss in 1H 2020)

Executive Chairman recently bought UK£300k worth of stock

Open Orphan plc Announces Ethics Approval for Covid-19 Human Challenge Study

Introducing Open Orphan (LON:ORPH), The Stock That Soared 388% In The Last Year

New 90-day high: UK£0.28

Open Orphan Plc's Subsidiary Venn Life Sciences Announces Contract Extension with Carna Biosciences

Open Orphan plc Announces Contract Renewal with Top-3 Pharmaceutical Client Extending Its Consultancy Services to End of December 2021

How Much Of Open Orphan plc (LON:ORPH) Do Insiders Own?

Open Orphan plc Announces Board Changes, Effective on December 31, 2020

Calculating The Fair Value Of Open Orphan plc (LON:ORPH)

Open Orphan plc Announces the Signs of A £2.5 Million Contract by hVIVO

Analysts lower EPS estimates to -UK£0.021

New 90-day high: UK£0.20

Open Orphan plc Announces £4.3 Million Contract to Conduct Human Viral Challenge Study

Open Orphan plc to Report First Half, 2020 Results on Sep 30, 2020

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Descubre empresas que pagan buenos dividendos